ULTRAGENYX PHARMACEUTICAL INC (RARE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RARE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RARE | Board member and advisor to various life science companies; Independent Chairman | 68 | ["Advisor to various life science companies", "Chairman on the boards of Structure Therapeutics, Inc. and Prothena Corporation plc", "Executive Partner at Sofinnova Ventures", "Chairman, Chief Executive Officer, and President of InterMune, Inc.", "Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc.", "President of the pharmaceutical division of Elan Corporation, plc", "Chairman of the board of directors of Nuvation Bio", "Director on the boards of Intercept Pharmaceuticals, Inc and Seagan Inc.", "B.S. from the University of Miami", "M.B.A. from the University of North Carolina", "Strong operating executive with operational and strategic expertise in the global pharmaceutical market"] | ["Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PRTA | Director | 68 | ["Scientific expertise in biopharmaceutical research and/or in relevant medical fields", "Experience in the design and implementation of clinical studies in support of drug development", "Experience with regulation in the healthcare industry", "Experience overseeing and driving strategic direction and growth of an organization", "Experience or expertise in financial accounting and reporting processes or the financial management of an organization", "Experience with legal and ethical and public policy issues in the healthcare industry", "Service on a public company board other than Prothena\u2019s", "Experience in capital market transactions or mergers and acquisitions", "Experience in attracting and retaining top talent and building organizational culture"] | ["Compensation Committee"] | 2026 |